Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
EUSA Pharma (United Kingdom)
Homepage:
eusapharma.com
Alternate names:
EUSA Pharma (UK) Ltd,
EUSA Pharma Ltd,
EUSA Pharma, Inc.
ROR:
01p7jrr32
OpenAlex ID:
I4405270993
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead
2015
·
Véronique Minard-Colin
, Laurence Brugières
, et al.
·
Journal of Clinical Oncology
·
307
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
2021
·
Giuseppe Gritti
, Federico Raimondi
, et al.
·
Leukemia
·
216
PDF
The oncostatin M‐stromal cell axis in health and disease
2018
·
Nathaniel R. West
, Benjamin M. J. Owens
, et al.
·
Scandinavian Journal of Immunology
·
79
Development of asparaginaseErwinia chrysanthemifor the treatment of acute lymphoblastic leukemia
2014
·
Wanda L. Salzer
, Barbara L. Asselin
, et al.
·
Annals of the New York Academy of Sciences
·
75
Safety profile of asparaginaseErwinia chrysanthemiin a large compassionate‐use trial
2014
·
Paul V. Plourde
, Sima Jeha
, et al.
·
Pediatric Blood & Cancer
·
70
PDF
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials
2020
·
Frits van Rhee
, Corey Casper
, et al.
·
The Lancet Haematology
·
63
PDF
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
2022
·
Frits van Rhee
, Adam Rosenthal
, et al.
·
Blood Advances
·
56
Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
2019
·
Kirsi M. Manz
, Klaus Fenchel
, et al.
·
Advances in Therapy
·
31
PDF
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling
2022
·
Jean-François Rossi
, Hao-Chun Chiang
, et al.
·
Frontiers in Immunology
·
21
Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review
2024
·
Urszula Żebrowska
, Walentyna Balwierz
, et al.
·
Targeted Oncology
·
18
PDF
The role of tivozanib in advanced renal cell carcinoma therapy
2018
·
Bernard Escudier
, Camillo Porta
, et al.
·
Expert Review of Anticancer Therapy
·
16
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis
2022
·
Sudipto Mukherjee
, Karan Kanhai
, et al.
·
Leukemia
·
14
PDF
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry
2022
·
David C. Fajgenbaum
, Sheila K. Pierson
, et al.
·
British Journal of Haematology
·
8
Symptom burden in patients with idiopathic multicentric Castleman disease and its impact on daily life: an international patient and caregiver survey
2023
·
Sudipto Mukherjee
, Francis Shupo
, et al.
·
EClinicalMedicine
·
7
PDF
Measurement of Subvisible Particulates in Lyophilised Erwinia chrysanthemi l-asparaginase and Relationship with Clinical Experience
2014
·
David Gervais
, Tim Corn
, et al.
·
The AAPS Journal
·
6
PDF
Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease
2021
·
Sheila K Pierson
, Karan Kanhai
, et al.
·
Blood
·
5
Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain
2019
·
Sheila K Pierson
, Yue Ren
, et al.
·
Blood
·
5
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival
2015
·
Paul G. Richardson
, Nancy A. Kernan
, et al.
·
Transplantation and Cellular Therapy
·
4
PDF
Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity
2021
·
Jean-Francois Rossi
, Hao-Chun Chiang
, et al.
·
Blood
·
3
PDF
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
2021
·
Giuseppe Gritti
, Federico Raimondi
, et al.
·
Leukemia
·
3
PDF
Efficacy and safety of approved first-line tyrosine kinase inhibitor (TKI) treatment in patients with metastatic renal cell carcinoma (mRCC): A network meta-analysis based on phase II/III randomised clinical trials (RCTs).
2019
·
Kirsi Manz
, Klaus Fenchel
, et al.
·
Journal of Clinical Oncology
·
3
Internal Psychometric Validation of an International Burden of Illness Survey for Idiopathic Multicentric Castleman Disease
2024
·
Matthew Franklin
, Francis Shupo
, et al.
·
Oncology and Therapy
·
2
PDF
Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indications
2023
·
Jaro Wex
, Monika Szkultecka-Debek
, et al.
·
Orphanet Journal of Rare Diseases
·
2
PDF
EE550 Lifetime Cost of Orphan Therapies in Paediatric Indications in Europe
2023
·
J. Wex
, P. Holko
, et al.
·
Value in Health
·
1
PDF
Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
2023
·
Francis Shupo
, Keith R. Abrams
, et al.
·
PharmacoEconomics - Open
·
1
PDF
Show more works
View as search
Works count:
48
Citation count:
8,763
Year
Topic
Type